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Background: N-ethyl-N-nitrosourea mutagenesis was used to induce a point mutation in C57BL/6 J mice.
Pain-related phenotype screening was performed in 915 G3 mice. We report the detection of a heritable recessive
mutant in meiotic recombinant N1F1 mice that caused an abnormal pain sensitivity phenotype with spontaneous
skin inflammation in the paws and ears.
Methods: We investigated abnormal sensory processing, neuronal peptides, and behavioral responses after the
induction of autoinflammatory disease. Single-nucleotide polymorphism (SNP) markers and polymerase chain
reaction product sequencing were used to identify the mutation site.
Results: All affected mice developed paw inflammation at 4–8 weeks. Histological examinations revealed
hyperplasia of the epidermis in the inflamed paws and increased macrophage expression in the spleen and paw
tissues. Mechanical and thermal nociceptive response thresholds were reduced in the affected mice. Locomotor
activity was decreased in affected mice with inflamed hindpaws, and this reduction was attributable to the
avoidance of contact of the affected paw with the floor. Motor strength and daily activity in the home cage in the
affected mice did not show any significant changes. Although Fos immunoreactivity was normal in the dorsal horn
of affected mice, calcitonin gene-related peptide immunoreactivity significantly increased in the deep layer of the
dorsal horn. The number of microglia increased in the spinal cord, hippocampus, and cerebral cortex in affected
mice, and the proliferation of microglia was maintained for a couple of months. Two hundred eighty-five SNP
markers were used to reveal the affected gene locus, which was found on the distal part of chromosome 18.
A point mutation was detected at A to G in exon 8 of the pstpip2 gene, resulting in a conserved tyrosine residue
at amino acid 180 replaced by cysteine (Y180 C).
Conclusions: The data provide definitive evidence that a mutation in pstpip2 causes autoinflammatory disease in
an N-ethyl-N-nitrosourea mutagenesis mouse model. Thus, our pstpip2 mutant mice provide a new model for
investigating the potential mechanisms of inflammatory pain.
Keywords: N-ethyl-N-nitrosourea, Autoinflammation, pstpip2, Single-nucleotide polymorphism, Nociception,
Inflammatory pain* Correspondence: bmbai@gate.sinica.edu.tw
1Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan,
Republic of China
3Graduate Institute of Life Science, National Defense Medical Center, Taipei,
Taiwan, Republic of China
Full list of author information is available at the end of the article
© 2012 Chen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Chen et al. Journal of Biomedical Science 2012, 19:55 Page 2 of 15
http://www.jbiomedsci.com/content/19/1/55Background
Pain and hyperalgesia frequently result from peripheral
tissue injury or nerve damage [1,2]. These abnormal sen-
sory events arise partially from the action of inflamma-
tory mediators on peripheral terminals of nociceptive
primary sensory neurons [3,4]. Numerous molecules,
such as prostaglandins and bradykinin, are known to be
produced by tissue damage or inflammation and consid-
ered responsible for the activation and sensitization of
peripheral pain-signaling sensory neurons [5]. Newly
identified mediators include various factors produced
and released from non-neuronal cells, such as macro-
phages and immune cells. These factors can act at nu-
merous loci and play important roles in mediating
persistent pain states [6,7].
Chronic pain includes neuropathic pain, inflammation
pain, and cancer pain and is often not adequately treated
by currently available analgesics. Several mouse and rat
models have been used in the study of the mechanisms of
chronic pain [8]. Inflammatory pain can be induced in ani-
mals by complete Freund’s adjuvant (CFA) and carra-
geenan injection, which cause acute inflammatory pain
and chronic polyarthritis [8,9]. Chronic inflammation may
also lead to an enhanced A- and C-fiber response and be-
havioral hypersensitivity in the CFA injection animal
model [10]. Glial cells are excited by pro-inflammatory
cytokines and neuroactive factors, which have been shown
to maintain and induce chronic pain [11,12]. Inflamma-
tory diseases cause progressive damage to neighboring
nerve tissues and organs in humans [13,14]. In classic
neuroimmune diseases, such as multiple sclerosis and
acute disseminated encephalomyelitis, neuroantigen-
reactive lymphocytes escape immune tolerance, invade
the central nervous system, and are responsible for tissue
damage, demyelination, and axonal degeneration [15].
Recently, transgenic models have proven to be useful
experimental methods in the study of pain. The knock-
out of specific nociception-related genes has been used
to unravel the underlying mechanism of pain [16,17].
Treatment with N-ethyl-N-nitrosourea (ENU) efficiently
generates single-nucleotide mutations in mice, which
can then be screened for phenotypes of pain-related in-
flammatory disease. A systematic genome-wide and
phenotype-driven mouse mutagenesis program for gene
function has been described [18,19]. We participated in
a large-scale ENU mutagenesis program sponsored by
the National Science Council of Taiwan and Academia
Sinica. The aim of the present study was to identify
genes related to chronic inflammatory syndromes
induced by ENU in mice. Different nociceptive assay
screening procedures were used to compare wildtype
and ENU mutant mice and select abnormal nociceptive
function. Four different nociceptive assays were used to
test thermal and mechanical nociceptive sensitivity inENU-treated mice. The tail-flick and hot plate tests as-
sess thermal pain. The von Frey and tail pressure assays
assess mechano-sensitive nociception. We detected an
ENU-treated mouse line with a spontaneous inflamma-
tory syndrome, providing pathophysiological evidence in
the organs and tissue of the mutant mice. These mice
developed spontaneous inflammation in the extremities
at approximately postnatal weeks 4–5. We further inves-
tigated behavioral responses and neuronal peptides after
the induction of autoinflammatory disease. The mutant
mice displayed a Mayp/pstpip2 point mutation that
resulted in autoinflammatory disease. These mice have
been bred to the 10th generation, and a consistent
phenotype has been maintained.
Methods
Mice
ENU-treated mice were bred according to the three-
generation breeding scheme as described by Weber et al.
(2000). Briefly, C57BL/6 J (B6) male mice were given
three intraperitoneal ENU injections (100 mg/kg body
weight) to generate G0 mice. G0 mice were then mated
with normal B6 females to generate male G1 founder
mice. Normal B6 females were mated with male G1
founders to generate G2 mice. G2 females were then
backcrossed to male G1 mice to generate G3 offspring.
Four different nociceptive assays were used to test ther-
mal and mechanical nociceptive sensitivity in G3 mice.
All of the testing data were standardized, and values
greater or less than 2.5-times the standard deviation were
defined as deviant and subjected to a further heritability
test. The slow (or fast) response was defined as the re-
sponse value of the deviant higher (or lower) than the
mean. Mice with the phenotype selected from the screen-
ing protocol were mated with mice from the same gen-
etic background and bred to produce G4 mice. The G5
generation was outcrossed with C3H/HeN to dilute the
genetic background and produce F1 hybrid carrier mice.
The F1 generation was then intercrossed with siblings to
breed the affected N1F1 mice. The outcross strategy was
used for single-nucleotide polymorphism (SNP) map-
ping. The breeding and housing of the mice occurred in
the Mouse Mutagenesis Program Core facility of Aca-
demia Sinica under specific pathogen-free conditions.
The mice were maintained on a regular rodent diet. All
of the experiments were performed in accordance with
the guidelines of the Academia Sinica Institutional Ani-
mal Care and Utilization Committee (PicoLab Mouse
Diet 20 code 5058, PMI LabDiet, St. Louis, MO, USA).
Inflammation measurement
The width of the first digit in affected and unaffected
mice was measured from week 4 to week 20. Graph
paper with a 1 mm scaled grid was used as the
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pix 990). The width of the digit was calculated from
digital images using ImageJ software (National Institutes
of Health, Bethesda, MD, USA).Histology
Anesthetized animals were perfused with 0.9% NaCl and
subsequently 4% paraformaldehyde in 0.1 M phosphate-
buffered saline (PBS; pH 7.4), followed by decalcification
using 20% ethylenediaminetetraacetic acid, which was
frequently changed for 2 weeks. Histopathologic exami-
nations were performed followed by hematoxylin/eosin
(H&E) staining.X-ray analysis
To detect bone morphology in affected and unaffected
mice, X-ray radiography was used to identify the hind-
paws of the mice. The Radiography X-ray system (GTR
Labs, KV= 38, MAS= 1.25) and Kodak Medical X-ray
Film General Purpose Green (30.5 cm × 38 cm) were
used to expose the image.Magnetic resonance imaging
All magnetic resonance imaging (MRI) experiments
were performed using a 4.7 T Biospec 47/40 spectrom-
eter (Bruker, Germany) with an active shielding gradient
(20 G/cm, 80 μs rise time). Under isoflurane anesthesia
(1.5-2.0% in oxygen), the body temperature (37°) and re-
spiratory rate (40-55/min) of the mice were monitored
and maintained throughout the experiment. Multi-slice
T2-weighted images were obtained with a 2 cm field-of-
view, 1 mm slice thickness, and 128 × 128 data matrix.Mechanical nociceptive behavioral assays
The von Frey assay was used to assess mechanical noci-
ceptive sensitivity. A von Frey filament was attached to a
force transducer (Model 1601 C, IITC, Woodland Hills,
CA, USA). The hindpaw was poked with a von Frey fila-
ment until paw withdrawal was seen. The force that
initiated paw withdrawal was considered the threshold
value. The threshold of the von Frey test was determined
as the mean value from 10 trials.Tail-flick test
The tail-flick test was designed to assess thermal noci-
ceptive sensitivity using a tail-flick apparatus (Model
37360, Tail Flick Unit, Ugo Basile, Italy). The mice were
allowed 15 min to acclimatize to the apparatus. The heat
intensity was set to 15 units, and the cut-off time was
set to 22 s. The latency was recorded when the tail was
flicked away from the heat source.Hot plate test
This test was used to measure thermal nociception. A
commercially available hot/cold plate apparatus was
used (35100 Hot/Cold Plate, Ugo Basile, Italy). The hot
plate apparatus was switch on to heat the surface of the
hot plate to a constant temperature of 55 ± 0.2°C. The
mice were placed on the hot plate (20 cm diameter),
which was surrounded by a clear acrylic protective cas-
ing (25 cm height with an open top). The paw with-
drawal latency, reflected by hindpaw licking, flicking, or
jumping, was recorded.
CatWalk analysis
The gait of auto-inflammatory pain and wildtype mice
was detected using CatWalk methods (Noldus Informa-
tion Technology, Leesburg, VA, USA). The mice were
placed in a chamber with a glass floor, which have light
source alone the glass edge. The light could be reflected
internally to downward directions during the paw or tail
contact with the glass surface. The more reflected inten-
sity and more brighter pixels were revealed, the more
press is in the contact region. The movements of the test
mice were recorded by a video camera under the glass
floor. Paw contact with the floor was calculated using
ImageJ software.
Open field test
The mice were placed in Plexiglas chambers (48 cm ×
48 cm) that had a 16 × 16 array of horizontal sensors.
Vertical and horizontal motor activity was calculated as
the total number of beams breaks in the X-Y plane in
10 ms bins [20].
Rotarod test
A commercially available Rota Rod apparatus (47600
Rota-Rod, Ugo Basile, Italy) was used. The diameter of
the rotating rod was approximately 5 cm, which was
made of hard plastic material covered by gray rubber
foam. The lane width was 5 cm. The apparatus allowed
an accelerating speed of 4 rotations per minute (rpm) to
40 rpm in 300 s. The time to fall from the rotarod was
recorded.
Homecage scan
The homecage scanning system monitors daily behaviors
in mice when placed in a safe and comfortable environ-
ment (i.e., 12 h/12 h light/dark cycle with constant
temperature and humidity). Clever Sys HomeCageScan
TM3.0 software (Clever Sys., Inc., Reston, VA, USA) was
used for monitoring. Six behaviors, including feeding,
drinking, walking, rearing, hanging, and grooming, were
detected simultaneously by this system. The ratio of the
time engaged in each activity during the light and dark
periods was calculated and compared.
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To detect pathological changes in the affected mice, rat
anti-F4/80 antibody (eBioscience, San Diego, CA, USA),
rabbit anti-Iba1 antibody (Abbiotec, San Diego, CA,
USA), rabbit anti-CGRP antibody (Chemicon Inter-
national, Temecula, CA, USA), and rabbit anti-Fos anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
were used. Affected homozygous, control unaffected
homozygous, and heterozygous animals were anesthe-
tized and perfused with 0.9% NaCl and subsequently 4%
paraformaldehyde in 0.1 M PBS (pH 7.4). The skin,
paws, and organs were removed, postfixed for 72 h, sec-
tioned at 10 μm on a cryostat (Leica CM3050S, Leica
Microsystems, Nussloch, Germany), and processed for
immunohistochemistry. The sections were incubated
with 0.1% trypsin for 20 min at 37 °C. The sections were
then cooled to room temperature for 20 min. Normal
serum was added for 1 h, and the solution was reacted
with rat anti-F4/80 antibody overnight at 4 °C. Biotiny-
lated immunoglobulin G (IgG) was used for 1 h at room
temperature.
Immunohistochemistry was performed using avidin-
biotin elite solution for 1 h (ABC kit, Vector Laborator-
ies, Burlingame, CA, USA). The stainings were visualized
using 0.03% 3,3-diaminobenzidine (DAB) and 0.07%
H2O2 in Tris buffer (pH 7.4). The distribution and inten-
sity of immunoreactivities were analyzed using ImageJ
software.
SNP genotyping
Genomic DNA was purified from the tails using the
Puregene DNA purification kit (Gentra Systems, Minne-
apolis, MN, USA). Two hundred eighty-five genome-
wide mouse SNP markers were used to identify the
mutation site, and we selected nine SNP markers located
in the distal part of chromosome 18 for the fine map-
ping of SNP genotypes. All of the SNPs were genotyped
using a MassARRAY (Sequenom, San Diego, CA, USA).
Sequencing of polymerase chain reaction products
Genomic DNA was purified from the tails using the
Puregene DNA purification kit (Qiagen [Gentra Sys-
tems], Minneapolis, MN, USA). All PCR reactions were
performed with recombinant Taq DNA polymerase
(MBI Fermentas) for 35 cycles. The exons of candidate
genes (pstpip2) were amplified, and the primers of candi-
date genes were designed with primer3 software. All
PCR primers were synthesized by Research Biolabs
(Singapore). Using 2% ethidium bromide-stained agarose
gel electrophoresis, a 123–400 base pair (bp) PCR frag-
ment length of the affected sequence region was pro-
duced and excised for gel extraction. Genomic DNA was
extracted from the cutting gel using a DNA extraction
kit (Genemark). The extracted PCR product was dilutedto 1–3 ng/100 bp and contained 2 ng/μl as the template
for the sequence reaction (ABI PRISM 3700 DNA
Analyzer, Applied Biosystems, Foster City, CA, USA).
Data analysis
ImageJ image analysis software was used to quantify the
intensity of immunoreactivity in the regions of interest.
To prevent immunostaining variations in different sam-
ples, the values of the immunoreactivity intensity were
normalized by calculating the ratio of the intensity in re-
active tissues and inactive tissues (e.g., white matter).
Five standard unit areas (a 200 μm × 200 μm square)
were randomly assigned and placed on the region of
interest so that these five unit areas were covered as
evenly as possible on the region of interest. The immu-
noreactivities measured from these five unit areas were
averaged to obtain the mean immunoreactivity value in
specific regions of interest. Quantitative data were ana-
lyzed using unpaired t-tests. All of the data are expressed
as the mean ± SEM, and significant differences were
determined using Student’s t-test. Values of p< 0.05 were
considered statistically significant. One-way analysis of
variance (ANOVA) was used to analyze the incidence of
autoinflammation and onset of autoinflammation. When
appropriate, Tukey’s post hoc test was used.
Results
Mutant phenotype
A total of 915 G3 mice (463 male and 452 female) were
used to screen abnormal nociceptive responses. Eight of
the mice exhibited a fast nociceptive response. These
mice with abnormal nociceptive responses were selected
to generate G4 mice. The G4 mice were mated with G3
fathers and mothers as the backcross strategy to produce
G5 deviants. In the G5 generation, we selected the mice
with a hypersensitive nociceptive response for the pur-
pose of SNP mapping. These mutant mice were then
outcrossed with C3H/HeN mice to produce the N1 gen-
eration. Intercross breeding was conducted to breed the
affected homozygous mice. In the N1F1 generation
(n= 62), eight female and two male mutant mice showed
an abnormal phenotype (i.e., spontaneous skin inflam-
mation in the four paws and ears). The offspring of N2
mice (i.e., the affected N1F1 mice outcrossed with C3H/
HeN mice) did not display a mutant phenotype. The
percentage of affected mice (20.6%, 18 affected mice
among 87 N2F1 offspring) in the N2F1 generation indi-
cated that the autoinflammatory syndrome was a reces-
sive mutation.
The affected homozygous mutant mice all showed
spontaneous inflammatory signs, including red, swollen,
and deformed paws (Figure 1A, a). X-ray analysis
revealed bone destruction and shadows that indicated
enlarged soft tissue in affected mice (Figure 1A, b).
Figure 1 Phenotype of paw morphology in unaffected and affected mice. Mouse detected by X-ray (A, b), MRI (A, c), and H&E staining
(A, d). (A) (a) Clinical symptoms of edematous inflammation and necrosis of the digits (arrows). (b) Radiography of a paw in an affected mouse
shows bone destruction, and the shadow shows enlarged soft tissue. (c) Affected mice exhibited indistinct signals of swollen soft tissue revealed
by MRI. (d) Inflamed phalanges of H&E stains in affected mice. The arrows show hyperplasia of the epithelium. (A, e-h) Paw development in
unaffected offspring from week 6 to week 9. (B, a-h) Comparison of respective phenotypes in unaffected mice. (C) Thickness of the digits in the
inflamed forelimb in mice with autoinflammation and unaffected mice. (D) Thickness of the digits in the inflamed hindlimb in affected and
unaffected mice. (E) Percentage of penetrance in each limb in affected mice. (F) Age of onset of clinical symptoms in affected mice.
Abbreviations: LF, left forelimb; RF, right forelimb; LH, left hindlimb; RH, right hindlimb.
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abnormal compared with the paws of unaffected mice
(Figure 1A, c). H&E staining showed proliferation in the
epithelial layer of the paw, and abnormal, deeply dense
cells were found in the inflamed area (Figure 1A, d).
Figure 1B, e-h, shows the condition of the paw in an
affected mouse from week 6 to week 9. The phenotypes
of the unaffected mice that were littermates of affected
mice and heterozygous for the mutation are shown in
Figure 1B. Six affected mice and four unaffected mice
were used in the X-ray analysis. Two affected mice and
two unaffected mice were evaluated by MRI. Seven
affected mice and four unaffected mice were used in the
H&E staining study. The mutant mice developed paw
deformities that began in week 5 to week 8. Subse-
quently, the mice developed thickened, dystropic hind-
paws. The mutant paws displayed inflammation
symptoms in the digits that also affected the widths of
the digits. Figure 1C shows the thickness of the digits in
the inflamed forelimbs in affected mice (n= 20) and un-
affected mice (n= 8). Figure 1D shows the thickness of
the digits in the inflamed hindlimbs in affected mice
(n= 20) and unaffected mice (n= 8). The data analysisshowed that the affected mice had significantly thicker
paws than wildtype mice. The long-term development of
the thickness of the paws in the fore- and hindlimbs in
the affected mice also showed that this syndrome was ir-
reversible. The percentage of penetrance in each limb of
the affected mice showed that most of the affected mice
had autoinflammation symptoms in the hindlimbs
(Figure 1E; intercross mice, n= 30; N1F1 mice, n =18;
N2F1 mice, n= 10). Figure 1E shows the mean± SEM
percentage of the incidence of total autoinflammation in
the four limbs in intercross, N2F1, and N1F1 mice. One-
way ANOVA indicated a significant difference
(F3,116 = 27.71, p< 0.05) in intercross mice. Furthermore,
the post hoc tests revealed a significant difference be-
tween the forelimbs and hindlimbs (p< 0.05). In N1F1
mice, a one-way ANOVA revealed significant differences
between the left forelimb, right forelimb, left hindlimb,
and right hindlimb (F3,39 = 4.05, p< 0.05). However, in
N2F1 mice, one-way ANOVA revealed no significant dif-
ferences between the left forelimb, right forelimb, left
hindlimb, and right hindlimb (F3,71 = 1.93, p> 0.05). The
phenotype of the mutant mice could be identified as
early as postnatal week 4, and the first symptoms were
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Inflammation in the affected mice mostly occurred in
week 5.
Pathology of autoinflammation
Histologic analysis revealed that cell proliferation oc-
curred in the epithelial layer of the ears in affected mice
(Figure 2E) compared with unaffected mice (Figure 2A).
Cell accumulation was detected in the kidneys of affected
mice (Figure 2F and G, arrow) compared with unaffected
mice (Figure 2B and C). In the spleen, more megakaryo-
cytes appeared in the red pulp of affected mice
(Figure 2H, arrow and inset) compared with unaffected
mice (Figure 2D). This megakaryocyte proliferation
phenomenon was also reported in chronic multifocal
osteomyelitis (cmo) mice [21]. The data from unaffected
mice are shown in Figure 2A-D. Seven affected mice and
four unaffected mice were used for H&E staining. Thus,
autoinflammatory disease appeared to cause megakaryo-
cyte proliferation in the red pulp of the spleen in H&E-
stained sections. Other histology data, including in the
skin, thymus, lungs, pancreas, liver, kidneys, heart, and
joints, were normal in affected mice.
Immunostaining of macrophage marker F4/80
We then sought to determine whether macrophages are
related to the observed inflammatory syndromes.
Immunostaining of the F4/80 antigen and counterstain-
ing with hematoxylin were used to detect morphological
macrophage changes in affected mice. The upper panel
of Figure 3 shows immunoreactivity in unaffected mice,
and the lower panel shows the phenotype of mice with
autoinflammatory disease. In the paw section, the affectedFigure 2 Pathology data of organ tissues in unaffected and affected m
the epithelial layer of the ear. (B, C, F, and G) Cell accumulations were det
(D and H) H&E staining demonstrated that autoinflammatory disease cause
(arrow; H and inset).mice exhibited an increase in F4/80 immunoreactivity
(Figure 3F and G, arrows). F4/80 immunoreactivity also
increased in the spleen in affected mice (Figure 3H,
arrows). Megakaryocytes were not reacted with F4/80 and
were detected in the red pulp (Figure 3H, arrowhead).
Differences in macrophage immunostaining were found
in the paw and spleen in eight affected mice and eight
unaffected mice. In the kidney section, F4/80 immunor-
eactivity was found in the proximal convoluted tubules
and renal cortex. We generally did not detect significant
differences in F4/80 immunoreactivity between un-
affected (Figure 3D and E) and autoinflammation mice in
the kidney (Figure 3I and J).
Behavioral, locomotor, and homecage tests
The von Frey test was used to identify nociceptive be-
havioral responses to mechanical stimuli following the
development of inflammation. The autoinflammation
mice showed a reduced intensity of mechanical force to
elicit signs of pain. Mechanical threshold in affected
mice was significantly lower than in unaffected mice
(affected mice, n= 8; unaffected mice, n= 8; p< 0.05;
Figure 4A) from postnatal week 5 to month 7. Thus,
mechanical nociceptive sensitivity was influenced by the
development of an autoinflammatory syndrome. Ther-
mal nociceptive responses were evaluated in the tail-flick
and hot plate tests. A significant difference in the tail-
flick response was observed between affected and un-
affected mice (unaffected mice, n= 9; affected mice,
n= 9; p< 0.05; Figure 4B). Affected mice had a lower
thermal threshold than unaffected mice. Thermal
threshold in the hot plate test increased in affected mice,
but the difference between affected and unaffected miceice. (A and E) Mice with autoinflammation showed proliferation in
ected in the kidney (square in F and arrow in enlarged picture in G).
d megakaryocyte proliferation in the red pulp of the spleen
Figure 3 F4/80 immunostaining and hematoxylin counterstaining of organ tissues of affected and unaffected mice. (A-E) The upper
panel shows immunoreactivity in unaffected mice. (F-J) The lower panel shows the immunoreactivity of mice with autoinflammatory disease. In
the paw section, the affected mice showed increased immunoreactivity (F and G, arrow). F4/80 immunoreactivity also increased in the spleen in
affected mice (H, arrow). Megakaryocytes were also detected in affected mice (H, arrowhead). In the kidney section, F4/80 immunoreactivity was
unchanged in unaffected mice (D and E) and mice with autoinflammation (I and J).
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mice, n= 10; p> 0.05; Figure 4B). These results indicate
that inflammatory processes may only affect mechanical
nociception, demonstrated in the von Frey test.
Locomotor activity was tested in affected and un-
affected mice as separate vertical and horizontal events
in the open field test. Both horizontal and vertical loco-
motor activity was significantly reduced in autoinflam-
mation mice (p< 0.01, horizontal events; p< 0.01,
vertical events; affected mice, n= 11; unaffected mice,
n= 22; Figure 4C). To test whether the changes in mech-
anical threshold and locomotor activity alter walking
steps, the size of paw contact with the floor was calcu-
lated in wildtype and affected mice using the CatWalk
protocol. Typical examples of paw prints during locomo-
tion in affected and unaffected mice are shown in
Figure 4D. The paw contact area results showed that the
inflamed limb in affected mice had a smaller contact
area (13.9 ± 1.9 mm2, n= 4) than the normal limb in un-
affected mice (87.2 ± 8.5 mm2, n= 7, p< 0.01).
The rotarod test was performed, the results of which
showed no significant difference between affected and
unaffected mice (affected mice, n= 10; unaffected mice,
n= 10; p> 0.05; Figure 4E). These results indicate that
the reduction of mechanical threshold and locomotor
activity in affected mice was not caused by motor
strength weakness or loss of coordination. General
health was assessed by monitoring daily activity in the
homecage. Drinking, feeding, grooming, hanging, rear-
ing, and walking were evaluated for 24 h while the mice
were kept in their homecage. The results showed no sig-
nificant differences in drinking, feeding, hanging, rear-
ing, or walking. However, grooming significantly
decreased (p< 0.05; n= 10; Figure 4F). These results in-
dicate that general health was normal in affected micecompared with unaffected mice. Grooming behavior
may be influenced by inflammatory conditions in the
inflamed paws.Fos and CGRP immunostaining in the spinal cord
c-fos is a cellular proto-oncogene that forms a complex
Fos protein that regulates the proliferation and differen-
tiation of most cell types and is used to detect neuronal
activity in response to noxious stimuli. We used a Fos
antibody to reveal neuronal activity in the spinal cord to
identify cellular changes in autoinflammation mice. The
mice were sacrificed at week 8, and the spinal cords of
affected and unaffected mice were removed and placed
in fixative buffer. Fos immunoreactivity at low and high
magnification in unaffected and affected mice is shown
in Figure 5A and B, respectively. We examined Fos ex-
pression in eight affected and five unaffected mice. No
significant differences in Fos expression were detected in
the dorsal horn of the spinal cord in these two groups of
mice (Table 1). A positive control used formalin injec-
tion into the paws of unaffected mice. Fos expression
was enhanced in the dorsal horn of the spinal cord
(Figure 5C). The chronic pain marker CGRP was used
to detect morphological changes in a previous study that
used a chronic inflammatory pain model in animals.
Normal CGRP immunoreactivity was found in un-
affected mice. The densest part of CGRP labeling was in
the laminar II layer of the dorsal horn of the spinal cord
(Figure 5D). We observed a dense distribution in five
unaffected mice. In affected mice, in addition to dense
CGRP labeling in lamina II, CGRP labeling was present
in the fibers of laminae III-V of the spinal cord
(Figure 5E). We observed a significantly increased dens-
ity of CGRP in the deep layers in six affected mice
Figure 4 Nociceptive and locomotor measurements. (A) Nociceptive response in unaffected (n= 5) and affected (n= 8) mice from 4 weeks to
7 months. A reduction of the latency in response to mechanical stimuli was detected in affected mice. (B) Tail-flick and hot plate tests. The
affected mice had a significantly shorter latency in the tail-flick test than unaffected mice. The latency in the hot plate test was longer in affected
mice but was not significantly different from unaffected mice. (C) Locomotor activity in affected and unaffected mice. Locomotion in both the
vertical (V) and horizontal (H) directions was lower in mice with autoinflammation than in unaffected mice. (D) Paw prints of affected and
unaffected mice in the CatWalk analysis. The arrow indicates the gait direction. Notice that the right paw of the affected mice has significantly
smaller paw prints than unaffected mice. (E) Rotarod test. No significant difference was found between the unaffected mice (n= 8) and affected
mice (n= 10). (F) Homecage scanning, including drinking, feeding, hanging, rearing, grooming, and walking. A significant difference was only
found in grooming between affected mice (n= 10) and unaffected mice (n= 10). Abbreviations: Unaff, unaffected mice; Aff, affected mice; V,
vertical event; H, horizontal event.
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in autoinflammation mice than in unaffected mice.
Microglia immunoreactivity in affected and unaffected
mice
Microglia play a key role in the maintenance of chronic
pain and can be activated in the neuropathic pain model.
To investigate changes in microglia in the central ner-
vous system, we used an IBa-1 antibody to detect the
density of microglia in mice with autoinflammation. The
microglia were stained in the spinal cord and brain slicesof unaffected and affected mice. Figure 6, upper left
panel, shows normal microglia in the cerebral cortex,
hippocampus, and spinal cord in unaffected mice. We
observed this pattern of microglia distribution in six un-
affected mice. In young affected mice at 5 weeks
(Figure 6, middle panel), the microglia exhibited enlarge-
ment and more fiber branching in the cerebral cortex,
hippocampus, and spinal cord than in unaffected mice.
We observed these phenomena in three young mice at
5 weeks. Microglia activity in five 20-week-old affected
mice were reduced to normal levels in the cerebral
Figure 5 Fos and CGRP immunoreactivity in the spinal cord in affected and unaffected mice. (A) No Fos expression was found in the
spinal cord in unaffected mice. (B) Fos immunoreactivity was detected in the dorsal horn in autoinflammation mice. (C) A positive control used
formalin injection into the paws of unaffected mice. Fos expression was enhanced in the dorsal horn of the spinal cord. (D) The densest part of
CGRP labeling was in the laminar II layer of the dorsal horn of the spinal cord. CGRP immunostaining revealed no detectable fibers in laminae
III-V in the spinal cord in unaffected mice. (E) CGRP-immunoreactive fibers in laminae III-V of the spinal cord were enhanced in autoinflammation
mice.
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pared with unaffected mice (Figure 6, right panel;
Table 1).
Identification of point mutation in autoinflammation mice
To identify the genetic mutation in autoinflammation
mice, genome-wide SNP mapping in 42 autoinflamma-
tion mice was performed for 285 SNP markers. A repre-
sentation of the linkage of the mutant phenotype is
shown in Figure 7A. Strong linkage was found in the
distal region of chromosome 18 (Figure 7A, arrow). The
mutation was localized between markers rs13483437
(78057994 bp) and rs13483455 (86422256 bp). We thenTable 1 Immunostainings of Fos, CGRP, and microglia in the
Fos CGRP
Ce
Unaffected 71.65 ± 13.84 (n= 5) 792.33 ± 60.20 (n= 5) 14
Affected (5 weeks) 102.19 ± 13.53 (n= 8) 1512.23 ± 231.54* (n= 6) 41
Affected (20 weeks) 50
Values are expressed as the density of immunostaining in a standard unit area of 2
between the unaffected and affected (5 weeks) groups. #p< 0.05, significant differeselected 10 SNP markers that narrowed the critical re-
gion to between rs13955 and rs13956 (1.7 Mb physical
distance; Figure 7B). In this region, five candidate genes
on the distal part of chromosome 18, including Pstpip2,
Nfatc1, Galr1, Mbp, and Cd 226 were sequenced using
the mouse DNA PCR product. Sequencing all 13 exons
of pstpip2/Mayp revealed a single A-to-G base mutation
in exon 8 (Figure 7C). The identified genotypes were the
following: G/G for affected homozygous mice, A/A for
unaffected homozygous mice, and an A/G double-peak
for unaffected heterozygous mice. The mutation was
present in all affected mice (n= 20). According to the
triplet genetic code, the mutant base was in the secondcentral nervous system of affected and unaffected mice
Microglia
rebral cortex Hippocampus Spinal cord
6.10 ± 8.42 (n= 6) 242.83 ± 17.75 (n= 6) 213.15 ± 13.13 (n= 6)
3.85 ± 5.61* (n= 3) 593.12 ± 18.92* (n= 3) 1023.89 ± 15.04 ** (n= 3)
0.79 ± 244.11 (n=5) 361.14 ± 57.71# (n= 5) 247.78 ± 24.71# (n= 5)
00 μm × 200 μm (mean ± SEM). *p< 0.05, **p< 0.01, significant difference
nce between the affected (5 weeks) and affected (20 weeks) groups.
Figure 6 Morphological microglial changes in unaffected and affected mice. Microglia were stained with an Iba-1 antibody. (Upper panel)
Microglia stainings in the cortex (primary somatosensory cortex), hippocampus (dentate gyrus), and spinal cord of unaffected mice. (Middle and
lower panels) Microglia stainings in respective brain areas of 5-week-old and 20-week-old affected mice.
Figure 7 Identification of point mutation in autoinflammation mice. (A) SNP mapping of autoinflammation mutation. The figure presents
the linkage of the mutant phenotype to the distal region of chromosome 18 (position 18.079.679). Two hundred eighty-five SNP markers are
plotted on the x-axis, ordered by chromosome location. The graph shows the percentage of C57BL/6 J genetic background calculated from
10 autoinflammation mice. (B) Fine mapping of chromosome 18. The proximal border is defined by marker rs13955, whereas the distal border is
defined by marker rs13956. The data were obtained from 28 affected mice. (C) Sequences of Pstpip2 gene from wildtype, heterozygous, and
homozygous mutant mice revealed a c.240AG(Y180C) mutation in exon 8. The C57BL/6 J and C3H carry an A at the respective position.
Heterozygous mice show a G/A double-peak. Autoinflammation mice carry only a G.
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amino acid substitution of tyrosine with cysteine at pos-
ition 180 (Y180C).
Discussion
The present study found an ENU-induced point muta-
tion in mice that caused autoinflammatory disease. We
found that the inflammatory phenotype was irreversible
in the paws, skin, and ears, and this autoinflammatory
disease caused an abnormal nociceptive response. Histo-
logical analysis revealed an increase in megakaryocytes
in the spleen and hyperplasia of the epidermis of the
paws in affected mice. Abnormal nociceptive behavior
was found in affected mice, but their motor coordination
and general daily activities in the homecages were nor-
mal compared with unaffected mice. Genetic mapping
indicated that the autoinflammation mice showed a
point mutation in pstpip2/Mayp located on the distal
part of chromosome 18 that caused an amino acid sub-
stitution from tyrosine to cysteine.
An ENU-induced genetic point mutation in Plcg2 and
pstpip2/Mayp that causes autoinflammatory disease in
mice has been reported [21,22]. A phospholipase Cγ2
(Plcg2) mutation resulted in severe spontaneous inflam-
mation and autoimmunity. The disease caused a gain-
of-function mutation in Plcg2, leading to hyperactive
external calcium entry in B cells and an expansion of in-
nate inflammatory cells [22]. Another study reported
that a mutation in Pstpip2 in so-called cmo mice resulted
in bone, cartilage, and skin inflammation. This autoin-
flammatory phenotype was derived from L98P amino
acid substitutions in Pstpip2 [21]. Grosse and colleagues
also reported an ENU-induced point mutation in macro-
phage actin-associated tyrosine phosphorylated protein
(Mayp/pstpip2) [23]. This Lupo mouse has a T-to-A base
pair change in psptpip2/Mayp caused by an amino acid
substitution from isoleucine to asparagine (I282N), lead-
ing to autoinflammatory disease [23]. Our autoinflam-
mation mice showed a similar phenotype as the
previously reported Lupo and cmo mice. However, the
mutation site (Y180C; see Figure 7) was not localized to
the same exon as previous findings. This indicates that
the psptpip2/Mayp gene has several domains, the muta-
tion of which causes dramatic functional impairments.
Autoinflammatory diseases are described as a group of
inherited disorders characterized by episodes of seem-
ingly unprovoked inflammatory attacks of an innate ori-
gin, mainly by neutrophils [24]. An abnormal immune
system causes a disruption of protection mechanisms
and other complications. Autoinflammatory diseases are
defined as illnesses caused by primary dysfunction of the
innate immune system [25] and are systemic disorders
characterized by apparently unprovoked inflammation in
the absence of high titer autoantibodies or antigen-specific T-lymphocytes [26]. Six autoinflammatory dis-
eases (i.e., pyogenic arthritis, pyoderma gangrenosum
and acne [PAPA], familial Mediterranean fever (FMF),
familial cold autoinflammatory syndrome [FCAS], Blau
disease, tumor necrosis factor receptor-associated peri-
odic syndrome (TRAPS), and hyper-IgD with periodic
fever syndrome [HIDS]) are all inherited as a single-gene
Mendelian disease [26,27]. PAPA syndrome is an
autosomal-dominant disease characterized by poly-
morphonuclear leukocyte invasion of the joints and skin
that produces destructive arthritis and skin lesions
[28,29]. PAPA syndrome is correlated with a pstpip1 mu-
tation that causes an attenuation of the PSTPIP1 associ-
ation with proline-glutamic acid-serine-threonine-rich
(PEST) protein tyrosine phosphatase. The mutant pro-
tein then results in a loss of function of the innate im-
mune response [30,31]. In a recent report, pyrin, the
FMF protein, was shown to interact with pstpip1 and
CD2 binding protein 1. Mutations of pstpip1 and CD2
binding protein 1 cause pyrin hyperphosphorylation,
which modulates normal immunoregulatory function
with other proteins [32]. Most patients with FMF carry
missense mutations in the C-terminal half of the pyrin
protein.
Proline, serine, and threonine phosphatase interacting
protein (PSTPIP), an actin- associated protein, is involved
in the assembly of the actin ring in the cytokinetic cleav-
age furrow. PSTPIP2 homo-oligomerizes, similar to the
PSTPIP1 association with the actin cytoskeleton. Both
PSTPIP1 and PSTPIP2 have a Fes/CIP4 homology do-
main and a putative coil-coil domain [33]. Macrophage
actin-associated tyrosine-phosphorylated protein (MAYP),
a protein related to PSTPIP2, regulates the CSF-1-
induced reorganization of the actin cytoskeleton [34].
MAYP belongs to the Pombe Cdc15 homology (PCH)
family of proteins that are involved in the regulation of
actin-based functions, inhibition of actin reorganization
into membrane ruffles, and stimulation of the formation
of filopodia by bundling actin in vitro and in vivo. The
coiled-coil region may be important for this function
because it contains a putative actin-binding domain and
is postulated to mediate MAYP oligomerization [35].
The analysis of the organs in autoinflammation mice
revealed an epithelial layer that was thinner than in nor-
mal mice. These autoinflammatory phenotypes were irre-
versible in the paws (see Figure 1). Radiography revealed
destruction of digital bones in affected mice. This
phenomenon is similar to a previous report of Lupo mice.
This bone destruction was also present in animals after
chronic treatment with inflammatory mediators [36-38].
Research in patients also indicated that bone destruction
could be induced after chronic inflammatory disease
[39]. This bone erosion symptom in inflammatory
patients derived from a significant increase in osteoclast
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We also used MRI in affected mice and observed an en-
largement of soft tissue in inflammatory areas. In a study
of human autoinflammatory disease in arthritic patients,
tissue edema, synovitis, bone erosion, and bone edema
were reported [41]. The affected mice in the present
study also exhibited infiltration by inflammatory material
in the paw section, causing edema in the epidermal and
dermal layers. This finding is similar to the previous
reports of cmo and Lupo mice. These imaging results
indicated that our autoinflammation mice possessed in-
flammatory characteristics. The incidence of inflamma-
tion was different between the fore- and hindlimbs, but
the mechanism of this phenotype is still unclear and
required further experimentation. The onset of clinical
inflammation in our affected mice occurred at 5 to
8 weeks, in contrast to cmo mice that exhibited inflam-
mation at 4 to 6 weeks and Lupo mice that exhibited in-
flammation at 42 ± 8 days.
Our present histological findings showed that after
onset of clinic signs the autoinflammation mice exhib-
ited an increase in megakaryocyte in the red pulp of the
spleen (Figure 3C and H). The spleen, a lymphoid organ,
plays a filtration role for animal blood and also stores
blood and monocytes. Hegen and colleagues reported
that the spleen had megakaryopoiesis inflammation in
white pulp and marked extramedullary hematopoiesis in
red pulp after arthritis induced in animals [42].
Zymosan-induced inflammation in mice resulted in the
accumulation of megakaryocytes and plasma-like cells
[43]. This evidence demonstrates that megakarocytes
can be stimulated after inflammation or infection. This
phenomenon of cell accumulation is similar to another
report of the interaction between megakarocytes and
platelets and internal pathogens and outside bacteria
during different stages of inflammation [44]. A molecu-
lar study also found a downregulation of platelets and
megakarocytes after genetic modification of the lipopoly-
saccharide (LPS)-binding Toll-like receptor 4 (TLR4)
[45]. Furthermore, in rheumatoid arthritis patients,
megakaryocytes regulated skeletal mass by inhibiting
bone resorption while simultaneously stimulating bone
formation and the regulation of osteoclastogenesis by
competing with cytokines [46]. This evidence suggests
that megakaryocytes play an important role in the in-
flammation signaling pathway. The abnormal megakar-
yocyte ratio found in our autoinflammation mice should
be further studied to identify cellular-level changes in
the spleen.
MAYP/PSTPIP2 has been described with regard to the
regulation of filopodia formation and motility in macro-
phages [34,35]. Our findings also present immunohisto-
logical macrophage marker F4/80 expression data that
demonstrated accumulated macrophages in the inflamedpaws and spleen. An inflammatory arthritis study also
indicated that macrophage and dendritic cells are rele-
vant components of the innate immune system [47,48].
A study of CFA-induced inflammation found an
increased macrophage phenotype in the spleen using
immunohistological and immunization methods [49].
Our present findings found an accumulation of macro-
phage marker F4/80 in the inflamed paws, reflecting an
increased number of macrophages, and this phenotype
may derive from arthritic disease. Our results are similar
to reports in Lupo mice and other reports that discuss
arthritic diseases [47].
The autoinflammatory syndrome that occurred in the
mutant mice in the present study was irreversible, and
this characteristic implies that this mutation could be a
new chronic inflammatory pain model in mice. Fos pro-
tein is a general neuronal activity marker that can be
expressed in an animal model of inflammation [50,51].
However, in the present study, the affected mice with in-
flammation syndrome did not exhibit altered Fos protein
expression compared with unaffected mice. A previous
chronic inflammation study also found that Fos activity
in the dorsal horn was gradually attenuated after the
acute inflammatory stage at 2–4 weeks [52]. Two days
after a carrageenin injection, a decrease in Fos activation
was found in the spinal cord [53], further suggesting that
our affected mice were not in the acute inflammation
stage. Altogether, these results may suggest that Fos pro-
tein expression in autoinflammation mice possibly
returned to normal levels, indicating that they were in a
stage of chronic inflammation recovery [54]. CGRP-
immunoreactive fibers have been shown to increase bi-
laterally in arthritic rats [55]. High expression of CGRP
protein has been reported to play an important role in
chronic central neuropathic pain [56] and be related to
the development of inflammation. In the present study,
we found that our autoinflammation mice exhibited a
large number of CGRP-like-immunoreactive fibers in
laminae III and V of the spinal cord. Results from a pain
study showed that noxious stimulus-induced hyperalge-
sia was not induced in CGRP-deficient mice after the
induction of inflammation [57], and CGRP-like immu-
noreactivity could also be enhanced 21 days after CFA
injection [58]. This evidence suggests that abnormal
CGRP expression in the spinal cord may reflect patho-
physiological mechanisms and involve the development
of nociceptive responses.
Astrocytes and microglia have been recognized as key
mediators of pathological and chronic pain [59]. Intra-
hippocampal injection of LPS and subcutaneous forma-
lin injection in mice led to an increased number and
activation of microglia in the central nervous system
[60,61]. These activated microglia could release proin-
flammatory cytokines that cause hypersensitivity in an
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microglial activation decreases neuropathy-induced
hypersensitivity in behavioral tests [63,64]. We also
verified microglial activation in affected mice at differ-
ent ages during the initial period of inflammation
(5 weeks). Microglia were activated in the spinal cord,
cerebral cortex, and hippocampus. The microglial acti-
vation in the acute stage of pain was similar to a previ-
ous study of experimental animals with chemical and
mechanical nerve root injury [65]. At 20 weeks, the
autoinflammation mice displayed reversible microglia
induction. This is also consistent with a study of micro-
glial activation that was attributable to their protective
role in the central nervous system following chronic
pain [59].
The present von Frey and locomotor activity tests sup-
ported the behavior observed in autoinflammation mice.
We recorded mechanical nociceptive responses from
4 weeks to 7 months and found chronic hypersensitivity
responses in autoinflammation mice. Previous studies
also found persistent hypersensitivity in an animal model
of sciatic nerve ligation-induced chronic pain [66] and
spinal cord injury model [67]. Locomotor activity testing
has been suggested to be a reliable parameter for studies
of chronic pain [68]. Our autoinflammation mice also
exhibited a decrease in locomotor activity, indicating
that the affected mice suffered from chronic inflamma-
tory pain. The reduction of locomotor activity was not
attributable to changes in motor strength or motor co-
ordination. The rotarod test did not reveal any signifi-
cant differences between unaffected and affected mice.
Furthermore, homecage scanning of daily activity also
showed normal behavior in affected mice, such as drink-
ing, feeding, hanging, rearing, and walking. These results
indicate that the inflammatory symptoms did not signifi-
cantly interfere with daily behaviors, and these mice
were able to maintain general health. Altogether, our
results demonstrate another ENU-induced point muta-
tion that causes autoinflammatory disease. This mouse
strain may contribute to research in the pain field, espe-
cially in inflammatory pain studies.
Conclusions
Our ENU-induced mutation of pstpip2 revealed an auto-
inflammatory phenotype in the skin of the extremities.
Additionally, these mutant mice exhibited mechanical
allodynia. Pain symptoms caused by a mutation of the
pstpip gene have been reported in autoinflammatory dis-
ease (e.g., PAPA syndrome). The clinical features of this
syndrome include pyogenic arthritis, pyoderma, gangre-
nosum, and cystic acne [69]. Among these symptoms,
pyderma gangrenosum is a very painful disease of skin
[30]. Pain symptoms of PAPA syndrome have been
reported in a patient after a minor traffic accident, thefamily members of whom were diagnosed with a muta-
tion in the pstpip gene and confirmed as having PAPA
syndrome [70]. Compared with most animal models of
chemical-induced inflammatory pain, the present animal
model of spontaneous pain has a longer duration of
pain. Formalin- and carrageenan-induced pain have been
recognized as short-term inflammatory pain models.
CFA-induced inflammatory pain has been considered a
model of long-term inflammatory pain. However, ther-
mal and mechanical hyperalgesia induced by CFA was
reduced 14 days after the injection. Spontaneous inflam-
matory pain in the present pstpip2 mutant mice, mea-
sured by mechanical pain sensitivity, began in the 5th
week and lasted for 7 months. The edema caused by in-
flammation also began at the same time and lasted for at
least 22 weeks. These are the distinct features of the
present model that differ from other animal models of
chemical-induced inflammatory pain. Most experimental
animal models of inflammatory pain induced by chem-
ical injury do not mimic the clinical presentations of in-
flammatory pain in autoinflammatory disease. The
pathology of inflammation-related chronic pain has been
previously overlooked because of inadequate approaches
to examining this issue. Thus, our pstpip2 mutant mice
provide a new model for investigating the potential
mechanisms of inflammatory pain.
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